Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intramuscular Pfizer Comirnaty COVID-19 booster trial
ACTRN12624000294550Phase 4Recruiting
- Sponsor
- Medical Research Institute of New Zealand
- Start
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Medical Research Institute of New Zealand. Started Jul 2024; status: recruiting.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12624000294550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000294550.